The information in this article represents the first indication of a potential test for the onset of esophageal cancer (EC), the fastest-growing cancer in the United States. EC kills 94.5 percent of patients diagnosed. Unfortunately, until EC has reached stage IV, no symptoms present themselves to the patient. A routine screening procedure that might be developed from testing for a methylated Reprimo gene would be vital.
Les Coleman Westerly, R.I.
From the Nature Index
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.